2-FDCK

2-FDCK

2-FDCK, also known as 2-Fluorodeschloroketamine, is a dissociative anesthetic that belongs to the arylcyclohexylamine class of drugs. It is a close structural analog of ketamine, a well-known dissociative anesthetic, and shares many of its properties. 2-FDCK is a relatively new research chemical, and there is limited information available about its pharmacology and effects on the human body.

Chemical Structure:

The chemical formula for 2-FDCK is C13H16FNO, and its molecular weight is 221.28 g/mol. Its structure is closely related to that of ketamine, with a fluorine atom substituted at the 2 position of the phenyl ring.

Physical Properties:

2-FDCK is a white crystalline powder that is soluble in water, ethanol, and propylene glycol. It has a melting point of 163-164°C and a boiling point of 374.1°C at 760 mmHg.

Pharmacology:

Like ketamine, 2-FDCK acts as an NMDA receptor antagonist, meaning it blocks the activity of the N-methyl-D-aspartate (NMDA) receptor in the brain. This receptor plays a key role in regulating the transmission of pain signals and is involved in various other functions such as learning, memory, and mood regulation. By blocking the NMDA receptor, 2-FDCK can induce dissociative anesthesia, which can cause a sense of detachment from one’s body and surroundings, as well as alterations in perception and thought.

Effects:

The effects of 2-FDCK are similar to those of ketamine but are reported to be less potent and shorter-lasting. Users have described feelings of euphoria, dissociation, and hallucinations. The onset of effects is typically rapid, with peak effects occurring within 20-30 minutes and lasting for several hours. The exact dose required to produce these effects is not well established, and the optimal dosage may vary depending on individual factors such as weight, tolerance, and other drugs or substances used concurrently.

Safety:

As a relatively new research chemical, there is limited information available about the safety profile of 2-FDCK. However, like other dissociative anesthetics, it has the potential to cause a range of adverse effects, including nausea, vomiting, dizziness, confusion, and memory loss. In addition, long-term use may be associated with neurological damage and cognitive impairment. As with any research chemical or drug, it is essential to use caution and follow safe practices when handling and administering 2-FDCK.

Conclusion:

In summary, 2-FDCK is a dissociative anesthetic that is structurally similar to ketamine. It acts as an NMDA receptor antagonist and can produce dissociative anesthesia, euphoria, and hallucinations. However, its effects are reported to be less potent and shorter-lasting than ketamine. While research into the safety and efficacy of 2-FDCK is ongoing, it is important to use caution and follow safe practices when working with this research chemical.